Telmisartan Stella

Telmisartan

Treatment of essential HTN in adults. Reduction of CV morbidity in adults w/ manifest atherothrombotic CV disease (history of CHD, stroke, or peripheral arterial disease) or type 2 DM w/ documented target organ damage.

Adult Treatment of essential HTN 40 mg once daily, can be increased to max 80 mg once daily if target BP is not achieved. Reduction of CV morbidity 80 mg once daily; close BP monitoring upon initiation. Patient w/ mild to moderate hepatic impairment Max: 40 mg once daily.

May be taken with or without food.

Hypersensitivity. Biliary obstructive disorders. Concomitant use w/ aliskiren-containing products in patients w/ DM or renal impairment (GFR <60 mL/min/1.73 m²). Severe hepatic impairment. 2nd & 3rd trimester of pregnancy.

Increased risk of severe hypotension & renal insufficiency in patients w/ bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney. Periodic monitoring of K & creatinine serum levels is recommended when used in patients w/ impaired renal function. Risk of symptomatic hypotension in vol- &/or Na-depleted patients. Dual blockade of renin-angiotensin-aldosterone system (RAAS) through combined use of ACE inhibitors, angiotensin II receptor blockers or aliskiren is not recommended. ACE inhibitors & angiotensin II receptor blockers should not be used concomitantly in patients w/ diabetic nephropathy. Risk of acute hypotension, hyperazotaemia, oliguria, or rarely acute renal failure in patients whose vascular tone & renal function depend predominantly on RAAS activity. Not recommended in patients w/ primary aldosteronism. Caution in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy. Hypoglycaemia may occur during treatment in diabetic patients treated w/ insulin or antidiabetics. Consider appropriate blood glucose monitoring. May cause hyperkalaemia. Close monitoring of serum K in at risk patients is recommended. Less BP-lowering effect in patients of African American ethnicity. Excessive BP reduction in patients w/ ischaemic cardiopathy or ischaemic CV disease could result in MI or stroke. May impair ability to drive or operate machinery. Do not give to patients w/ cholestasis, biliary obstructive disorders or severe hepatic impairment. Caution in patients w/ mild to moderate hepatic impairment. Patients w/ severe renal impairment or undergoing haemodialysis. Patients w/ recent kidney transplantation. Not recommended during the 1st trimester of pregnancy & breast-feeding. Childn & adolescents <18 yr.

Uncommon: Upper resp tract infection including pharyngitis & sinusitis, UTI including cystitis; anaemia; hyperkalaemia; depression, insomnia; syncope; vertigo; bradycardia; hypotension, orthostatic hypotension; dyspnoea, cough; abdominal pain, diarrhoea, dyspepsia, flatulence, vomiting; hyperhidrosis, pruritus, rash; myalgia, back pain (eg, sciatica), muscle spasms; renal impairment including acute renal failure; chest pain, asthenia (weakness); increased blood creatinine.

Increases in digoxin peak plasma & trough conc. Significant increase in serum K w/ K-sparing diuretics (eg, spironolactone, eplerenone, triamterene or amiloride), K supplements, or K-containing salt substitutes. Reversible increases in serum lithium conc & toxicity. Reduced antihypertensive effect w/ NSAIDs (eg, acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors & non-selective NSAIDs). Prior treatment w/ high-dose diuretics eg, furosemide (loop diuretic) & hydrochlorothiazide (thiazide diuretic) may result in vol depletion, & in risk of hypotension when initiating therapy. Higher frequency of adverse events w/ combined use of ACE inhibitors, angiotensin II receptor blockers, or aliskiren. Potentiated hypotensive effect w/ baclofen, amifostine. Aggravated orthostatic hypotension w/ alcohol, barbiturates, narcotics, or antidepressants. Reduced antihypertensive effect w/ systemic corticosteroids.

Angiotensin II Antagonists

C09CA07 - telmisartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

P₁S₁S₃